EO1001 demonstrates up to ~40-fold greater potency than osimertinib in EGFR ECD-mutant tumor modelsEO4426 (tezacitabine) demonstrates selective targeting of DNA replication machinery and resistance to ...
For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib ...
Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion ...
Morning Overview on MSN
New bowel cancer approach keeps disease at bay for 3 years
Every patient enrolled in a groundbreaking rectal cancer trial has remained disease-free for more than three years after ...
RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the independent presentation of new preclinical data at the 2026 American Association for ...
Discover the very best turn-based RPGs to play in 2026, from Baldur's Gate 3 to Dragon Quest 11 ...
This study characterizes several novel activities of SARS-CoV-2 helicase nsp13, providing valuable insights into potentially new functions of this essential RNA-processing enzyme in the virus life ...
In this valuable study, the authors develop new approaches to investigate mRNA imprinting, a phenomenon in which RNA-protein complexes form in the nucleus to influence the fate of transcripts in the ...
Chemotherapy can make food taste metallic, bland, or unpleasant, turning everyday eating into a clinical challenge that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results